Nerviano Medical Sciences Srl Announces Rozlytrek® (Entrectinib) Royalty Agreement
Nerviano Medical Sciences Srl Announces Rozlytrek® (Entrectinib) Royalty Agreement – NMS to receive up to $21 Million – Financing proceeds will be used to advance NMS’s proprietary PARP1-selective, non-trapping, brain-penetrant, inhibitor NMS-293, as well as its selective PARP7 inhibitor atamparib NERVIANO, Italy and NEW YORK, NY, March 31, 2025 – Nerviano Medical Sciences S.r.l. (NMS), and […]
Nerviano Medical Sciences’ presentation from the 8th Annual DDR Inhibitors Summit is now available
We’re thrilled to share the presentation delivered by Lisa Mahnke, MD, PhD, CEO/President, Nerviano Medical Sciences, Inc; CMO, Nerviano Medical Sciences, Srl, Guest Speaker at the recent 8th Annual DDR Inhibitors Summit. Lisa’s presentation “Exploring Next-Gen PARP Inhibitors without PARP Trapping” focused on preclinical features and preliminary clinical data of the highly unique non-trapping, PARP1 […]
Nerviano Medical Sciences is presenting at the 8th Annual DDR Inhibitors Summit
We are excited to announce that Lisa Mahnke, MD, PhD, CEO/President, Nerviano Medical Sciences, Inc; CMO, Nerviano Medical Sciences, Srl, will participate as a Guest Speaker at the 8th Annual DDR Inhibitors Summit taking place in Boston from January 28-30. Lisa’s presentation Exploring Next-Gen PARP Inhibitors without PARP Trapping, scheduled for January 30th at 3:45 […]
Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma
Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma NERVIANO, Italy and BOSTON, Mass.,13 January 2025 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., […]
Nerviano Medical Sciences S.r.l. Announces the Launch of a New Clinical Trial to Evaluate NMS-153 in Combination with Atezolizumab and Clinical Trial Supply Agreement with Roche
Nerviano Medical Sciences S.r.l. Announces the Launch of a New Clinical Trial to Evaluate NMS-153 in Combination with Atezolizumab and Clinical Trial Supply Agreement with Roche NMS-153: A clinical-stage, potent and highly selective small molecule inhibitor of Monopolar Spindle 1 (MPS1), and cGAS/STING pathway activator, with differentiated mechanism of action and potential for First-in-Class/Best-in-Class The […]
Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results
Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results Agreement reached with Merck KGaA to gain back the full rights of NMS-293 Available clinical data support NMS-293 as an ideal partner for combination with DNA-damaging agents like chemotherapies or ADC payloads: NMS […]
Nerviano Medical Sciences Announces Strategic acquisition of atamparib, a Phase II-ready PARP7 Inhibitor, from Ribon Therapeutics
NERVIANO, Italy and BOSTON, Mass., November 14, 2024 – Nerviano Medical Sciences S.r.l. (NMS) – a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Srl – a global leader in oncological innovation with a leading position in PARP1 inhibitor clinical development in brain cancer, is […]
Nerviano Medical Sciences announces publication of the paper “Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents”
We are pleased to announce the publication of our review article titled “Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents” in Pharmaceuticals, as part of the Special Issue “Evaluation of the Antitumor Mechanism of Armed Antibodies: 2nd Edition“. This paper explores the latest advances in the use of DNA-interacting agents […]
We are speaking at the 15th Annual WADC San Diego 2024!
We are speaking at the 15th Annual WADC 2024 in San Diego . partnering event in San Diego , 4 – 7 Nov. 2024 We look forward to your presence to explore future partnership opportunities. * * * * * Contact: Valsasina Barbara : Barbara.Valsasina@demo111.axxiem.com Lupi Rosita: rosita.lupi@demo111.axxiem.com * * * * * About NMS […]
NMS Group S.p.A. Announces Change in Shareholding Structure, Board of Directors and Statutory Auditors to Accelerate Growth and Innovation
NERVIANO, IT, September 11, 2024 – NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces today a change to its shareholding structure, leading to a restructured board of directors and statutory auditors. The Fondazione Regionale per la Ricerca Biomedica (FRRB), established by the Lombardy Regional Government with an aim to promote […]
